SOM230 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cluster Headache - Episodic and Chronic
Conditions
Cluster Headache - Episodic and Chronic
Trial Timeline
Oct 31, 2016 → Sep 25, 2018
NCT ID
NCT02619617About SOM230 + Placebo
SOM230 + Placebo is a phase 2 stage product being developed by Novartis for Cluster Headache - Episodic and Chronic. The current trial status is terminated. This product is registered under clinical trial identifier NCT02619617. Target conditions include Cluster Headache - Episodic and Chronic.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02619617 | Phase 2 | Terminated |
Competing Products
8 competing products in Cluster Headache - Episodic and Chronic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab 300 mg + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| candesartan cilexetil + placebo | AstraZeneca | Phase 2 | 52 |
| Bosutinib + Imatinib | Pfizer | Phase 3 | 76 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 74 |
| Eptinezumab | Lundbeck | Phase 3 | 74 |
| Methylprednisolone | Brain Biotech | Approved | 77 |